STRATIFIED HOST-DIRECTED THERAPY FOR DRUG-RESISTANT TUBERCULOSIS: A RANDOMIZED CONTROLLED MULTI-CENTRE TRIAL

Project Information

DRTB-HDT

Grant agreement ID: 847465

DOI

10.3030/847465

EC signature date 19 December 2019

Start date 1 January 2020

End date 31 December 2025

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 9 969 012,25

EU contribution

€ 9 969 012,25

Coordinated by

SCHWEIZERISCHES TROPEN UND PUBLIC HEALTH INSTITUT
Switzerland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (1)

Website

Aurum will be responsible for creating and hosting the website for the project and consortium

Publications

Peer reviewed articles (5)

Economic burden of chronic obstructive pulmonary disease and post-tuberculosis sequelae in low- and middle-income countries: a database compiled from a systematic review and meta-analysis

Author(s): Yuling Lin, Alexandra Walker, Marguerite Batta, Sierra Ottilie-Kovelman, Anna Duchenko, Curdin Brugger, Olivia Keiser, Robert S Wallis, Klaus Reither, Fabrizio Tediosi, Marina Antillon
Published in: BMJ Public Health, Issue 2, 2024, Page(s) e000441, ISSN 2753-4294
Publisher: BMJ
DOI: 10.1136/bmjph-2023-000441

DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis

Author(s): Nestani Tukvadze, Sehlomola Mashatole, Anne Jacobs, Tlhago Ngwanto, Norbert Heinrich, Annelies Van Rie, Valeriu Crudu, Elena Tudor, Leila Goginashvili, Elmira Ibraim, Celso Khosa, Pauline Howell, Shakira Rajaram, Kinita Naidoo, Stefan Niemann, Klaus Reither, Robert S. Wallis
Published in: BMC Infectious Diseases, Issue 25, 2025, ISSN 1471-2334
Publisher: BioMed Central
DOI: 10.1186/s12879-025-11072-5

Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae

Author(s): Nicolas A Menzies, Matthew Quaife, Brian W Allwood, Anthony L Byrne, Anna K Coussens, Anthony D Harries, Florian M Marx, Jamilah Meghji, Debora Pedrazzoli, Joshua A Salomon, Sedona Sweeney, Sanne C van Kampen, Robert S Wallis, Rein M G J Houben, Ted Cohen
Published in: The Lancet Global Health, Issue Volume 9, Issue 12, 2021, Page(s) Pages e1679-e1687, ISSN 2214-109X
Publisher: Elsevier BV
DOI: 10.1016/s2214-109x(21)00367-3

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

Author(s): Robert S. Wallis; Sibuse Ginindza; Trevor Beattie; Nishanee Arjun; Morongwe Likoti; Modulakgotla Sebe; Vinodh A. Edward; Mohammed Rassool; Khatija Ahmed; Katherine Fielding; Bintou A. Ahidjo; Mboyo D. T. Vangu; Gavin Churchyard
Published in: PLoS ONE, Issue 17(2), 2022, ISSN 1932-6203
Publisher: Public Library of Science
DOI: 10.1371/journal.pone.0252097

Host-directed immunotherapy of viral and bacterial infections: past, present and future

Author(s): Robert S. Wallis, Anne O’Garra, Alan Sher, Andreas Wack
Published in: Nature Reviews Immunology, Issue 23, 2024, Page(s) 121-133, ISSN 1474-1733
Publisher: Nature Publishing Group
DOI: 10.1038/s41577-022-00734-z